FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3178411050> ?p ?o ?g. }

• W3178411050 abstract "Radiotherapy (RT) is a primary treatment modality that is used in 50% of cancer patients. Clinically, tumor radioresistance poses a challenge to achieve complete anti-tumor response following conventional photon-RT. Diverse mechanisms have been proposed to underpin radioresistance. However, targeting these aberrant pathways to overcome tumor radioresistance remains a clinical challenge. Here, we investigate if proton beam therapy (PBT) invokes differential cellular responses compared to photon-RT in a broad panel of radioresistant (RR) cancer cell lines. We generated isogenic RR human cancer cell lines: 22Rv1 prostate cancer, FaDu hypopharyngeal cancer and C666-1 nasopharyngeal cancer, by exposure of respective wildtype (wt) to 90 Gy photon-RT (2 Gy x 45 fr). RR was confirmed by clonogenic survival, with surviving fraction ratio (SFRR/SFwt) at 1-4 Gy (range: 1.2-1.8). Whole exome sequencing (100x; Illumina NovaSeq) was performed to profile RR-associated mutational drivers. We performed transcriptomic and proteome profiling of cellular response such as non-homologous end-joining (NHEJ) and homologous recombination (HR) repair at 1-24 h after 4 Gy PBT (2.5 MeV, 2 Gy/min) and photon-RT (0.66 MeV, 0.716 Gy/min). At baseline, we found common mutations and differential activation of several pro-survival (Akt, mTOR), epithelial-mesenchymal transition (EMT) (PDGF, TGFb) and DNA repair pathways (ATM, BRCA1, NHEJ- and HR-associated) genes in RR- relative to wt-22Rv1. Post-photon-RT, we observed residual persistent DNA repair in wt-cell lines up to 48 h. In contrast, repair in RR-cell lines was more proficient, as shown by recovery of γH2AX, ATM-Chk2 within 6 h, with significant NHEJ activation (DNA-PKcs). Next, we observed that RR-cell lines were more sensitive to PBT than photon-RT (mean SF4Gy PBT/SF4Gy photon-RT = 0.61), with delayed DNA repair (γH2AX) observed up to 48 h, which may be attributed to the difficulty in repairing PBT-induced DNA damage. This phenomenon, seems to be primarily orchestrated by decreased NHEJ activation combined with diminished cell cycle checkpoint arrest (p21) and anti-apoptotic (bcl-2) signaling. Radiosensitization by PBT was however not observed in wt (mean SF4Gy proton/SF4Gy photon = 1.14), corroborated by gene and protein expression of DDR-related pathways. We observed dysregulation of multiple pathways relating to EMT and DNA repair in our panel of RR-cancer cell lines, compared to the wt-counterparts. Additionally, we show the potential for PBT to overcome radioresistance in these models by targeting the DNA repair machinery. Due to the high cost of PBT, precise patient stratification is needed to ensure that PBT is applied only to patients who benefit significantly from this procedure over photon-RT. Our preliminary data represents a proof-of-concept for feasibility of patient stratification to PBT.Citation Format: Pek Lim Chu, Eugenia L.L. Yeo, Dennis J.J. Poon, Ce-belle Chen, Minqin Ren, Saumitra Vajandar, Dewi Susanti, Hong Qi Tan, Sung Yong Park, Thomas Osipowicz, Kwok Wai Lo, Stanley K. Liu, Khee Chee Soo, Melvin Lk Chua. Proton irradiation sensitizes cancer cell lines with acquired radioresistance by exploiting differentially dysregulated DNA damage response (DDR) pathways [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 3062." @default.
• W3178411050 created "2021-07-19" @default.
• W3178411050 creator A5015233832 @default.
• W3178411050 creator A5018412533 @default.
• W3178411050 creator A5023049795 @default.
• W3178411050 creator A5026936521 @default.
• W3178411050 creator A5030893970 @default.
• W3178411050 creator A5042981740 @default.
• W3178411050 creator A5046557030 @default.
• W3178411050 creator A5053082742 @default.
• W3178411050 creator A5062344524 @default.
• W3178411050 creator A5070461179 @default.
• W3178411050 creator A5072871494 @default.
• W3178411050 creator A5078925966 @default.
• W3178411050 creator A5089870055 @default.
• W3178411050 creator A5090210992 @default.
• W3178411050 date "2021-07-01" @default.
• W3178411050 modified "2023-10-15" @default.
• W3178411050 title "Abstract 3062: Proton irradiation sensitizes cancer cell lines with acquired radioresistance by exploiting differentially dysregulated DNA damage response (DDR) pathways" @default.
• W3178411050 doi "https://doi.org/10.1158/1538-7445.am2021-3062" @default.
• W3178411050 hasPublicationYear "2021" @default.
• W3178411050 type Work @default.
• W3178411050 sameAs 3178411050 @default.
• W3178411050 citedByCount "0" @default.
• W3178411050 crossrefType "proceedings-article" @default.
• W3178411050 hasAuthorship W3178411050A5015233832 @default.
• W3178411050 hasAuthorship W3178411050A5018412533 @default.
• W3178411050 hasAuthorship W3178411050A5023049795 @default.
• W3178411050 hasAuthorship W3178411050A5026936521 @default.
• W3178411050 hasAuthorship W3178411050A5030893970 @default.
• W3178411050 hasAuthorship W3178411050A5042981740 @default.
• W3178411050 hasAuthorship W3178411050A5046557030 @default.
• W3178411050 hasAuthorship W3178411050A5053082742 @default.
• W3178411050 hasAuthorship W3178411050A5062344524 @default.
• W3178411050 hasAuthorship W3178411050A5070461179 @default.
• W3178411050 hasAuthorship W3178411050A5072871494 @default.
• W3178411050 hasAuthorship W3178411050A5078925966 @default.
• W3178411050 hasAuthorship W3178411050A5089870055 @default.
• W3178411050 hasAuthorship W3178411050A5090210992 @default.
• W3178411050 hasBestOaLocation W31784110501 @default.
• W3178411050 hasConcept C121608353 @default.
• W3178411050 hasConcept C134935766 @default.
• W3178411050 hasConcept C143425029 @default.
• W3178411050 hasConcept C153911025 @default.
• W3178411050 hasConcept C185592680 @default.
• W3178411050 hasConcept C502942594 @default.
• W3178411050 hasConcept C54355233 @default.
• W3178411050 hasConcept C552990157 @default.
• W3178411050 hasConcept C58962609 @default.
• W3178411050 hasConcept C62478195 @default.
• W3178411050 hasConcept C81885089 @default.
• W3178411050 hasConcept C86554907 @default.
• W3178411050 hasConcept C86803240 @default.
• W3178411050 hasConceptScore W3178411050C121608353 @default.
• W3178411050 hasConceptScore W3178411050C134935766 @default.
• W3178411050 hasConceptScore W3178411050C143425029 @default.
• W3178411050 hasConceptScore W3178411050C153911025 @default.
• W3178411050 hasConceptScore W3178411050C185592680 @default.
• W3178411050 hasConceptScore W3178411050C502942594 @default.
• W3178411050 hasConceptScore W3178411050C54355233 @default.
• W3178411050 hasConceptScore W3178411050C552990157 @default.
• W3178411050 hasConceptScore W3178411050C58962609 @default.
• W3178411050 hasConceptScore W3178411050C62478195 @default.
• W3178411050 hasConceptScore W3178411050C81885089 @default.
• W3178411050 hasConceptScore W3178411050C86554907 @default.
• W3178411050 hasConceptScore W3178411050C86803240 @default.
• W3178411050 hasLocation W31784110501 @default.
• W3178411050 hasOpenAccess W3178411050 @default.
• W3178411050 hasPrimaryLocation W31784110501 @default.
• W3178411050 hasRelatedWork W2033795765 @default.
• W3178411050 hasRelatedWork W2097372335 @default.
• W3178411050 hasRelatedWork W2150586003 @default.
• W3178411050 hasRelatedWork W2415398623 @default.
• W3178411050 hasRelatedWork W2514738721 @default.
• W3178411050 hasRelatedWork W2774282247 @default.
• W3178411050 hasRelatedWork W3001197855 @default.
• W3178411050 hasRelatedWork W3129640797 @default.
• W3178411050 hasRelatedWork W4303621977 @default.
• W3178411050 hasRelatedWork W4319017166 @default.
• W3178411050 isParatext "false" @default.
• W3178411050 isRetracted "false" @default.
• W3178411050 magId "3178411050" @default.
• W3178411050 workType "article" @default.